Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation

Kamil Gotfryd, Galina Skladchikova, Eugene E Lepekhin, Vladimir Berezin, Elisabeth Bock, Peter S Walmod

23 Citations (Scopus)

Abstract

Background: The anti-epileptic drug valproic acid (VPA) has attracted attention as an anti-cancer agent.Methods: The present study investigated effects of VPA exposure on histone deacetylase (HDAC) inhibition, cell growth, cell speed, and the degree of Erk1/2 phosphorylation in 10 cell lines (BT4C, BT4Cn, U87MG, N2a, PC12-E2, CSML0, CSML100, HeLa, L929, Swiss 3T3).Results: VPA induced significant histone deacetylase (HDAC) inhibition in most of the cell lines, but the degree of inhibition was highly cell type-specific. Moreover, cell growth, motility and the degree of Erk1/2 phosphorylation were inhibited, activated, or unaffected by VPA in a cell type-specific manner. Importantly, no relationship was found between the effects of VPA on HDAC inhibition and changes in the degree of Erk1/2 phosphorylation, cell growth, or motility. In contrast, VPA-induced modulation of the MAPK pathway downstream of Ras but upstream of MEK (i.e., at the level of Raf) was important for changes in cell speed.Conclusions: These results suggest that VPA can modulate the degree of Erk1/2 phosphorylation in a manner unrelated to HDAC inhibition and emphasize that changes in the degree of Erk1/2 phosphorylation are also important for the anti-cancer properties of VPA.

Original languageEnglish
JournalBMC Cancer
Volume10
Issue number1
Pages (from-to)383-95
Number of pages12
ISSN1471-2407
DOIs
Publication statusPublished - 21 Jul 2010

Fingerprint

Dive into the research topics of 'Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation'. Together they form a unique fingerprint.

Cite this